This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Inflammation	Hypoxia-inducible factor 1 α subunit inhibitor (HIF1AN; FIH1); hypoxia-inducible factor prolyl hydroxylase 1 (EGLN2; HIF-PH1; PHD1)	<i>In vitro</i> and mouse studies suggest inhibiting HIF1AN and HIF-PH1 could help treat inflammatory diseases by suppressing IL-1 β signaling. In cell culture, a pan-hydroxylase inhibitor or small interfering RNA knockdown of HIF1AN or HIF-PH1 decreased IL-1 β -induced activation of NF- κ B compared with vehicle or no knockdown. In mice, the pan-hydroxylase inhibitor prevented NF- κ B activation. Mass spectrometry analysis identified hydroxylated components of tumor necrosis factor receptor-associated factor 6 (Traf6) that linked IL-1 β to NF- κ B activation. Next steps could include testing hydroxylase inhibition in models of inflammatory diseases.	Patent and licensing status unavailable	Scholz, C.C. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Oct. 21, 2012; doi:10.1073/pnas.1309718110 Contact: Cormac T. Taylor, University College Dublin, Dublin, Ireland e-mail: cormac.taylor@ucd.ie
SciBX 6(44); doi:10.1038/scibx.2013.1265 Published online Nov. 14, 2013				